
Sign up to save your podcasts
Or


In this episode of Financial Modeler’s Corner, host Paul Barnhurst (aka the FP&A Guy) sits down with Frank David, an expert at the intersection of corporate strategy, clinical medicine, and biotech research. They discuss the unique challenges of financial modeling in the biopharma industry, the importance of understanding patient populations, and how drug development strategy influences financial decision-making.
Frank David is the Founder and Managing Director of Pharmagellan, a consulting firm specializing in biotech financial modeling and valuation. With a background as a physician scientist, Frank has extensive experience advising biopharma teams and investors. He also teaches at Tufts University and is the lead author of The Pharmagellan Guide to Biotech Forecasting and Valuation and The Pharmagellan Guide to Analyzing Biotech Clinical Trials.
Expect to Learn:
Here are a few quotes from the episode:
This episode explored the complexities of biotech financial modeling. Frank shared why traditional financial modeling approaches don’t always work in the biotech industry and how strategic decision-making relies heavily on understanding patient needs, regulatory pathways, and risk assessment.
Follow Frank:
Follow Paul:
Follow Financial Modeler's Corner
Sign up for the Advanced Financial Modeler Accreditation Today and receive 15% off by using the special show code ‘Podcast’.
Visit https://bit.ly/497oAqW and use the code “Podcast” to save 15% when you register.
In today’s episode:
[01:14] - Introduction to the Episode
[02:02] - Meet Frank David
[04:17] - Financial Modeling Horror Story
[09:38] - Understanding Biotech Financial Models
[13:57] - Biotech Forecasting and Valuation
[18:15] - Where to Start When Analyzing a Drug Project
[24:52] - Risk-Adjusted Modeling in Biotech
[32:01] - Advice for Modelers in Biotech
[40:56] - Fun & Rapid-Fire Questions
[49:32] - How to Connect with Frank David
By Paul Barnhurst AKA The FP&A Guy4.9
1515 ratings
In this episode of Financial Modeler’s Corner, host Paul Barnhurst (aka the FP&A Guy) sits down with Frank David, an expert at the intersection of corporate strategy, clinical medicine, and biotech research. They discuss the unique challenges of financial modeling in the biopharma industry, the importance of understanding patient populations, and how drug development strategy influences financial decision-making.
Frank David is the Founder and Managing Director of Pharmagellan, a consulting firm specializing in biotech financial modeling and valuation. With a background as a physician scientist, Frank has extensive experience advising biopharma teams and investors. He also teaches at Tufts University and is the lead author of The Pharmagellan Guide to Biotech Forecasting and Valuation and The Pharmagellan Guide to Analyzing Biotech Clinical Trials.
Expect to Learn:
Here are a few quotes from the episode:
This episode explored the complexities of biotech financial modeling. Frank shared why traditional financial modeling approaches don’t always work in the biotech industry and how strategic decision-making relies heavily on understanding patient needs, regulatory pathways, and risk assessment.
Follow Frank:
Follow Paul:
Follow Financial Modeler's Corner
Sign up for the Advanced Financial Modeler Accreditation Today and receive 15% off by using the special show code ‘Podcast’.
Visit https://bit.ly/497oAqW and use the code “Podcast” to save 15% when you register.
In today’s episode:
[01:14] - Introduction to the Episode
[02:02] - Meet Frank David
[04:17] - Financial Modeling Horror Story
[09:38] - Understanding Biotech Financial Models
[13:57] - Biotech Forecasting and Valuation
[18:15] - Where to Start When Analyzing a Drug Project
[24:52] - Risk-Adjusted Modeling in Biotech
[32:01] - Advice for Modelers in Biotech
[40:56] - Fun & Rapid-Fire Questions
[49:32] - How to Connect with Frank David

962 Listeners

4,709 Listeners

1,932 Listeners

376 Listeners

2,682 Listeners

1,091 Listeners

161 Listeners

124 Listeners

333 Listeners

1,297 Listeners

796 Listeners

49 Listeners

394 Listeners

25 Listeners

7 Listeners